Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 1 Trials for Alvespimycin (DB12442)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00089362Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsTreatment